Connection

Marcel Müller to Protease Inhibitors

Back to Details
This is a "connection" page, showing publications Marcel Müller has written about Protease Inhibitors.
Marcel Müller
Connection Strength
0.101
Protease Inhibitors
  1. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 04 16; 181(2):271-280.e8.
    View in: PubMed
    Score: 0.065
  2. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 2020 05 21; 64(6).
    View in: PubMed
    Score: 0.016
  3. Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity. J Infect Dis. 2015 Mar 15; 211(6):889-97.
    View in: PubMed
    Score: 0.011
  4. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011 Oct; 7(10):e1002331.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.